If ChatGPT’s calculation is correct then yes we cannot conclude with certainty about atorvastatin but the signal in its favor is quite strong.
Regarding neurocognitive decline, I think that obicetrapib is the most promising: Obicetrapib (CETP inhibitor for dyslipidemia)
In the absence of obicetrapib, ezetimibe is my best guess and I think that’s what I’ll start using. Reasoning here: Parkinson's disease - #89 by adssx
Some PD researchers and practicians now support statin cessation in PD patients. See also this discussion: Rapamycin and risk of cardiovascular disease - #3064 by adssx